Board of Directors 2018-11-07T12:47:32+00:00


Chris Indermaur


Chris has over 30 years of experience in large Australian companies in Engineering, Business Development and Commercial roles. He previously held the role of General Manager of Strategy and Development at Alinta Ltd. Chris holds a Bachelor of Engineering (Mechanical) and a Graduate Diploma of Engineering (Chemical) from the West Australian Institute of Technology (now Curtin University).

Chris also holds a Bachelor of Laws and a Master of Laws from the Queensland University of Technology and a Graduate Diploma in Legal Practice from the Australian National University.

Chris is currently Chairman of Poseidon Nickel Limited, a Non-Executive Director of Aerison Pty Ltd and was previously a Non-Executive Director of the Prime Health Group prior to its sale to Sonic Health Care.

Peter Carlisle

Vice Chairman

Mr. Peter Carlisle serves as Managing Director of Olympics & Action Sports at Octagon Worldwide, Inc. and Octagon, Inc. Mr. Carlisle oversees contract negotiations, athlete endorsements and licensing and merchandising opportunities.

Mr. Peter Carlisle serves as Managing Director of Olympics & Action Sports at Octagon Worldwide, Inc. and Octagon, Inc. Mr. Carlisle oversees contract negotiations, athlete endorsements and licensing and merchandising opportunities. He has also develops content-driven programs for athletes that are re-defining the term “athlete marketing.” He has more than 15 years of experience in the industry, he has received numerous awards and recognitions, including being named to SportsBusiness Journal’s “Forty Under 40” Hall of Fame, its 20 most influential people in action sports and its 20 most influential sports agents. Sporting News named him to its Power 100 list, and Mr. Carlisle was named one of the best lawyers in America in sports law, including earning the Sports Law Lawyer of the Year in 2012.

Franklyn G Prendergast

Non-Executive Director

Franklyn G. Prendergast, M.D., Ph.D. was the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, to its Physician Advisory Board.

Dr Prendergast is the former Chair of the Department of Biochemistry and Molecular Biology and the former director for research at Mayo Clinic from 1989-1992. From 1989-1996, he was a member of the Board of Governors for Mayo Clinic, Rochester. From 1999-2007 inclusive, he was member of Mayo Clinic’s Executive Committee, the senior most internal governance committee for the entire Mayo system. He served on Mayo Clinic’s Board of Trustees continuously between 1992-2009. He was recognized as a Mayo Distinguished Investigator in 1988 and is the director emeritus, Mayo Clinic Cancer Center (1995-2006) and director emeritus for the Mayo Clinic Center for Individualized Medicine (2008-2012). Dr. Prendergast retired from Mayo Clinic in December of 2014.

Dr Prendergast has been a member of the Eli Lilly Company Board of Directors since 1995. He served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH. He was a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).

Dr Prendergast’s reputation and experience within US healthcare, especially clinical research.

“I am looking forward to beginning my relationship with Medibio Limited. I am thrilled they are bringing an objective, evidence based test, to the field of mental illness, where none has existed before. This is a ground-breaking area and I am excited to be involved.”

Andrew Maxwell

Non-Executive Director

Medical device expert. Commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health and created a global medical device company.

For 10 years, Andrew led the global growth of Global Kinetics Corporation Ltd (GKC) as Managing Director and Chief Executive Officer. The GKC team commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health and created a global company with a market leading product for the remote measurement and reporting of the movement disorder symptoms of Parkinson s disease – the Parkinson’s KinetiGraph (PKG).

Patrick Kennedy

Non-Executive Director
Patrick Kennedy is a former member of the U.S. House of Representatives and a leading U.S. political voice on mental illness, addiction, and other brain diseases.  He is also co-founder of One Mind for Research, which seeks to increase resources and collaboration in brain research, and founder of the Kennedy Forum, which advances a roadmap to transform Mental Health and addiction care.

Patrick J. Kennedy is a former member of the U.S. House of Representatives (D-R.I.) and the nation’s leading political voice on mental illness, addiction, and other brain diseases.  During his 16-year career representing Rhode Island in Congress, he fought a national battle to end medical and societal discrimination against these illnesses, highlighted by his lead sponsorship of the Mental Health Parity and Addiction Equity Act of 2008.  As a chief sponsor of one of the major pieces of legislation of 2008, the Mental Health Parity Act, a bill requiring most group health plans to provide coverage for the treatment of mental illnesses that is comparable to what they provide for physical illnesses. Mr. Kennedy was also recently appointed to President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis.  His political career and his brave openness about his own health challenges provide unique expertise to Medibio.

“Medibio’s technology is truly groundbreaking, and has the potential to fundamentally change the mental health system for the better. That’s why I am proud to be part of this team,” said Kennedy. “This is a company that is truly on the cutting edge, and their diagnostic and analytic tools will give clinicians the power to treat patients more effectively, using better data, and with a focus on better outcomes.”

Following his 8th term serving in the U.S. Congress, Kennedy has become a leading advocate for increased Mental Health & Addiction treatment coverage in the United States.  He is a co-founder of One Mind for Research, which seeks to increase resources and collaboration in brain research and founder of the Kennedy Forum which advances a roadmap to transform mental health and addiction care.

Mr. Kennedy served three terms in the Rhode Island State legislature before he was elected as a Democratic member of the United States House of Representatives from 1995 to 2011.  Kennedy served on the Armed Services Committee and the Appropriations committee, where he served on the subcommittee on Veterans Affairs and the Subcommittee on Labor, Health and Human Services, Education, and the NIH. While in Congress, he was a vocal advocate for healthcare reform and the chief sponsor of the 2008 Mental Health Parity and Addiction Equity Act.

Michael Phelps

Non-Executive Director

Michael is an advocate for Mental Health and since retiring from competitive swimming has dedicated his time, fame, and focus on philanthropic causes that include Mental Health.

Since retiring from competitive swimming in 2016, Phelps has actively sought to raise awareness around mental health.  Prior to his appointment to Medibio’s Board of Directors, Mr. Phelps worked with its team of world-class doctors and medical experts to explore ways in which Medibio’s technology could help address the challenges associated with the identification and treatment of various mental health issues.  Mr. Phelps used Medibio’s technology to analyze his own personal datasets and experienced firsthand how it is uniquely positioned to address the challenges associated with mental health diagnosis.

“I am honored to accept this appointment because I have personally experienced Medibio’s technology and believe it can help make a profound impact in diagnosing mental health and empowering people to seek the help and support they may need,” said Phelps.  “In sports, there is so much focus on the physical aspects of performance, and athletes are analyzed from head to toe.  But for many athletes, mental health has not been a topic of focus, and the data analysis aspect of it has been missing up until now.  I personally suffered from mental health challenges from my teenage years on, and only fairly recently—after reaching a point of desperation—did I acquire the understanding, treatment, and support I needed, which has truly changed my life.  For me, self-awareness, from a mental health standpoint, is empowerment.  But I’ve seen firsthand—in sports and beyond—how difficult it is for people to understand, discuss, and confront stress, anxiety, and mental health concerns, all of which can seem like an insurmountable barrier to getting the help and support that is needed. I feel that the ease and objectivity with which Medibio’s technology can accurately help to diagnose mental health will make a profound difference in people’s lives. I want to help others who are dealing with these challenges and make the process for them to take action easier and more understandable.”   

Widely regarded as one of the greatest athletes of all-time, Mr. Phelps has dedicated his time, fame, and focus to a number of philanthropic causes including water-safety, mental health, and anti-doping initiatives. His advocacy for mental health recently earned the recognition of the Substance Abuse and Mental Health Services Administration’s (“SAMHSA”) as the Honorary Chairperson of National Mental Health Awareness Day 2017 and recipient of the organizations Special Recognition Award. In addition, Mr. Phelps is an Ambassador for the Child Mind Institute’s #MyYoungerSelf social media campaign in an effort to help end the stigmas associated with mental health and learning disorders.

Mr. Phelps established the Michael Phelps Foundation in 2008 with the focus on growing the sport of swimming and promoting healthy and active lifestyles, especially for children. The Foundation’s signature program – im –  was developed in collaboration with and Michael Phelps Swimming to provide water-safety instruction, recreational pool activities, and swim training, as well as health, wellness, and goal-setting education.

David B. Kaysen

CEO, Medibio

Dave has 35+ years of experience leading and managing both domestic and international emerging growth companies.  He has achieved consistent and solid results with bio-pharmaceutical, medical device and clinical software/IT companies. David is also experienced in the FDA approval process, leading products in revenue growth.

From 2006 until 2013, Kaysen served as President, CEO and director of Uroplasty, Inc., a Minnesota-based publicly traded global medical device company, which he guided through successful clinical trials and grew annual sales from $6.7M in 2007 to $22M in 2013. He also successfully completed four rounds of financing, raising $26.5M to fund company growth.

In previous roles, Kaysen served as President, CEO, and director of Advanced Duplications Services, LLC; President, Chief Executive Officer and a director of Diametrics Medical, Inc., and President, CEO, and director of Rehabilicare, Inc., a global rehabilitation and neuromodulation company, where he grew sales from $4M to $73M in sales over a ten-year period.

In addition to his role on the Board of Sun BioPharma, Mr. Kaysen currently serves in Board of Director roles for privately held healthcare companies, InterRad Medical and Spinal Singularity, and as an Advisory Board member for Ireland-based Atlantic Therapeutics and Minneapolis-based EXB Solutions.

Brian Mower

CFO, Interim CEO, Medibio

21 years experience in senior finance, including 17 years in commercializing innovative medical technologies; KPMG, Iomed(AMEX: IOX), DJO, & ToraxMedical (acquired by Johnson & Johnson).

Board Members on Medibio